



December 16, 2013

Press Release

Company	RaQualia Pharma Inc.	
Representative	CEO	Naoki Tani (JASDAQ Code : 4579)
Contact	Board of Director, Senior Vice President	Akihiro Furuta (TEL. 0569-84-0700)

RaQualia Grants Patent License to H. Lundbeck (Denmark)

RaQualia Pharma Inc. (RaQualia) today announced that the company has agreed to license global rights of a particular patent held by RaQualia to H. Lundbeck A/S (CEO: Ulf Wiinberg, headquartered in Copenhagen, Denmark) for their use of the licensed claims in any Lundbeck products.

Under the terms of the agreement, RaQualia will receive an upfront fee and royalties on commercial sales.

Though this step will not require any changes to the current issue of the business forecast, the Company is examining the influence of the recent gain on sales of the investment securities, announcing the revised forecast for the Full Year as soon as the numbers are fixed.

About H. Lundbeck:

H. Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the entire value chain throughout research, development, production, marketing and sales of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy, Huntington's, Alzheimer's and Parkinson's diseases.

Establishment	1915
Representative	Chief Executive Officer & President Ulf Wiinberg
Address	Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark
Number of Employees	About 6,000 (consolidated)

####